Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Tirzepatide

These are related to the Tirzepatide news, in which you can learn about the latest trends in Tirzepatide and related information industry, to help you better understand and expand Tirzepatide market.
  • Dual Incretin Revolution: Tirzepatide’s Mechanism And Clinical Impact in Obesity & Diabetes

    Dual Incretin Revolution: Tirzepatide’s Mechanism And Clinical Impact in Obesity & Diabetes

    2025-06-19

    Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents a breakthrough in obesity and type 2 diabetes treatment. This article explores its synergistic mechanism, superior clinical outcomes, and global market potential. It also highlights how Unibest supports global pharma companies with API sourcing, licensing, and regulatory services in the incretin drug space. Read More
  • Drug Briefing: Tirzepatide

    Drug Briefing: Tirzepatide

    2025-05-29

    Query Drug：TirzepatideQuery Time：2025-05-29 16:35:52*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Read More
  • Future Medications for Obesity

    Future Medications for Obesity

    2025-05-26

    Obesity is a global health crisis affecting over 650 million people worldwide. But there's hope on the horizon. Recent breakthroughs in understanding how our gut and pancreatic hormones regulate appetite and blood sugar have led to the development of exciting new medicines to treat obesity and relat Read More
  • Tirzepatide Approved by NMPA for Type II Diabetes

    Tirzepatide Approved by NMPA for Type II Diabetes

    2024-05-21

    On May 21st, the Chinese National Medical Products Administration (NMPA) approved Tirzepatide (brand name Mounjaro), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Lilly, for the improvement of glycemic control in adults wi Read More